Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Lymphoma | Primary research

Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells

Authors: Evgeniya V. Dolgova, Daria D. Petrova, Anastasia S. Proskurina, Genrikh S. Ritter, Polina E. Kisaretova, Ekaterina A. Potter, Yaroslav R. Efremov, Sergey I. Bayborodin, Tatiana V. Karamysheva, Margarita V. Romanenko, Sergey V. Netesov, Oleg S. Taranov, Aleksandr A. Ostanin, Elena R. Chernykh, Sergey S. Bogachev

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

We have characterized the human cell line arised from the Epstein–Barr virus (EBV) positive multiple myeloma aspirate subjected to the long-term cultivation. This cell line has acquired the ability to form free-floating spheres and to produce a xenograft upon transplantation into NOD/SCID mice.

Methods

Cells from both in vitro culture and developed xenografts were investigated with a number of analytical approaches, including pathomorphological analysis, FISH analysis, and analysis of the surface antigens and of the VDJ locus rearrangement.

Results

The obtained results, as well as the confirmed presence of EBV, testify that both biological systems are derived from B-cells, which, in turn, is a progeny of the EBV-transformed B-cellular clone that supplanted the primordial multiple myeloma cells. Next we assessed whether cells that (i) were constantly present in vitro in the investigated cell line, (ii) were among the sphere-forming cells, and (iii) were capable of internalizing a fluorescent TAMRA-labeled DNA probe (TAMRA+ cells) belonged to one of the three types of undifferentiated bone marrow cells of a multiple myeloma patient: CD34+ hematopoietic stem cells, CD90+ mesenchymal stem cells, and clonotypic multiple myeloma cell.

Conclusion

TAMRA+ cells were shown to constitute the fourth independent subpopulation of undifferentiated bone marrow cells of the multiple myeloma patient. We have demonstrated the formation of ectopic contacts between TAMRA+ cells and cells of other types in culture, in particular with CD90+ mesenchymal stem cells, followed by the transfer of some TAMRA+ cell material into the contacted cell.
Appendix
Available only for authorised users
Literature
1.
Dowling M, Kelly M, Meenaghan T. Multiple myeloma: managing a complex blood cancer. Br J Nurs. 2016;25(16):S18–28.PubMedCrossRef
2.
Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, et al. Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs. 2011;34(3):219–27.PubMedPubMedCentralCrossRef
3.
4.
Nilson K, Ponten J. Classification and biological nature of established human hematopoietic cell lines. Int J Cancer. 1975;15:321–41.CrossRef
5.
Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson B. Epstein–Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 1991;173:147–58.PubMedCrossRef
6.
Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res. 2000;24(8):681–703.PubMedCrossRef
7.
Dolgova EV, Shevela EY, Tyrinova TV, Minkevich AM, Proskurina AS, Potter EA, et al. Nonadherent spheres with multiple myeloma surface markers contain cells that contribute to sphere formation and are capable of internalizing extracellular double-stranded DNA. Clin Lymphoma Myeloma Leuk. 2016;16(10):563–76.PubMedCrossRef
8.
Alyamkina EA, Dolgova EV, Likhacheva AS, Rogachev VA, Sebeleva TE, Nikolin VP, et al. Exogenous allogenic fragmented double-stranded DNA is internalized into human dendritic cells and enhances their allostimulatory activity. Cell Immunol. 2010;262:120–6.PubMedCrossRef
9.
Dolgova EV, Proskurina AS, Nikolin VP, Popova NA, Alyamkina EA, Orishchenko KE, et al. “Delayed death” phenomenon: a synergistic action of cyclophosphamide and exogenous DNA. Gene. 2012;495(2):134–45.PubMedCrossRef
10.
Alyamkina EA, Nikolin VP, Popova NA, Minkevich AM, Kozel AV, Dolgova EV, et al. Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts. Cancer Cell Int. 2015;15:32.PubMedPubMedCentralCrossRef
11.
Dolgova EV, Efremov YR, Orishchenko KE, Andrushkevich OM, Alyamkina EA, Proskurina AS, et al. Delivery and processing of exogenous double-stranded DNA in mouse CD34+ hematopoietic progenitor cells and their cell cycle changes upon combined treatment with cyclophosphamide and double-stranded DNA. Gene. 2013;528:74–83.PubMedCrossRef
12.
Dolgova EV, Alyamkina EA, Efremov YR, Nikolin VP, Popova NA, Tyrinova TV, et al. Identification of cancer stem cells and a strategy for their elimination. Cancer Biol Ther. 2014;15(10):1378–94.PubMedPubMedCentralCrossRef
13.
Potter EA, Dolgova EV, Proskurina AS, Alexandra M, Efremov YR, Taranov OS, et al. A strategy to eradicate well-developed Krebs-2 ascites in mice. Oncotarget. 2016;7(10):11580–94.PubMedPubMedCentralCrossRef
14.
Dolgova EV, Potter EA, Proskurina AS, Minkevich AM, Chernych ER, Ostanin AA, et al. Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line. Stem Cell Res Ther. 2016;7(7):76.PubMedPubMedCentralCrossRef
15.
Van Belzen N, Hupkes PE, Doekharan D, Dorssers LCJ, Van Veer MB. Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkin’ s lymphoma. Leukemia. 1997;11:1742–52.PubMedCrossRef
16.
Uchiyaama M, Maesawa T, Yashima A, Ifabashi T, Ishida Y, Masuda T. Consensus primers for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell lymphomas. J Clin Pathol. 2003;56:778–80.CrossRef
17.
18.
19.
Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015;125(13):2095–100.PubMedPubMedCentralCrossRef
20.
21.
Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.PubMedPubMedCentralCrossRef
22.
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia. 2017;31(6):1446–9.PubMedPubMedCentralCrossRef
23.
Nishihori T, Song J, Shain KH. Minimal residual disease assessment in the context of multiple myeloma treatment. Curr Hematol Malig Rep. 2016;11(2):118–26.PubMedPubMedCentralCrossRef
24.
Alyamkina EA, Leplina OY, Ostanin AA, Chernykh ER, Nikolin VP, Popova NA, et al. Effects of human exogenous DNA on production of perforin-containing CD8+ cytotoxic lymphocytes in laboratory setting and clinical practice. Cell Immunol. 2012;276:59–66.PubMedCrossRef
25.
Dolgova EV, Efremov YR, Taranov OS, Potter EA, Nikolin VP, Popova NA, et al. Comparative analysis of pathologic processes developing in mice housed in SPF vs. non-SPF conditions and treated with cyclophosphamide and dsDNA preparation. Pathol Res Pract. 2015;211(10):754–8.PubMedCrossRef
26.
Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood. 1999;93(4):1435–7.PubMed
27.
Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353(8):811–22.PubMedCrossRef
28.
29.
30.
Tai Y-T, Dillon M, Song W, Leiba M, Li X-F, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–37.PubMedPubMedCentralCrossRef
31.
Mansurabadi R, Abroun S, Hajifathali A, Asri A, Atashi A, Haghighi M. Expression of hsa-MIR-204, RUNX2, PPARγ, and BCL2 in bone marrow derived mesenchymal stem cells from multiple myeloma patients and normal individuals. Cell J. 2017;19(Suppl 1):27–36.PubMedPubMedCentral
32.
Zhao P, Chen Y, Yue Z, Yuan Y, Wang X. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway. Leuk Res. 2017;57:20–6.PubMedCrossRef
33.
Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190–7.PubMedPubMedCentralCrossRef
34.
35.
Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, et al. PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351–67.PubMedPubMedCentralCrossRef
36.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.PubMedCrossRef
37.
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.PubMedCrossRef
38.
Proskurina AS, Orishchenko KE, Potter EA, Dolgova EV, Spaselnikova AV, Ritter GS, et al. Expression of genes of cytokines, transcription factors and differentiation antigens in human dendritic cells activated by double-stranded DNA. Vavilovskii Zhurnal Genet Selektsii. 2017;21(6):717–27. https://​doi.​org/​10.​18699/​VJ17.​289 (In Russian).CrossRef
39.
40.
41.
Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–17.PubMedCrossRef
42.
Morell CM, Strazzabosco M. Notch signaling and new therapeutic options in liver disease. J Hepatol. 2014;60(4):885–90.PubMedCrossRef
43.
Efremov YR, Proskurina AS, Potter EA, Dolgova EV, Efremova OV, Taranov OS, et al. Cancer stem cells: emergent nature of tumor emergency. Front Genet. 2018;9:544.PubMedPubMedCentralCrossRef
44.
45.
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526(7571):131–5.PubMedPubMedCentralCrossRef
46.
Muhammad N, Bhattacharya S, Steele R, Phillips N, Ray RB. Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23(12):3120–8.PubMedCrossRef
47.
Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant. 2012;18(1 Suppl):S27–32.PubMedPubMedCentralCrossRef
48.
49.
50.
Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci. 2006;103(9):3304–9.PubMedCrossRefPubMedCentral
51.
Wang Y, Volloch V, Pindrus MA, Blasioli DJ, Chen J, Kaplan DL. Murine osteoblasts regulate mesenchymal stem cells via WNT and cadherin pathways: mechanism depends on cell-cell contact mode. J Tissue Eng Regen Med. 2007;1(1):39–50.PubMedCrossRef
52.
Zhu Q, Zhang X, Zhang L, Li W, Wu H, Yuan X, et al. The IL-6–STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014;5(6):e1295.PubMedPubMedCentralCrossRef
53.
Al-toub M, Vishnubalaji R, Hamam R, Kassem M, Aldahmash A, Alajez NM. CDH1 and IL1-beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and human mesenchymal stem cells. Stem Cell Res Ther. 2015;6(1):135.PubMedPubMedCentralCrossRef
54.
Suzuki K, Chosa N, Sawada S, Takizawa N, Yaegashi T, Ishisaki A. Enhancement of anti-inflammatory and osteogenic abilities of mesenchymal stem cells via cell-to-cell adhesion to periodontal ligament-derived fibroblasts. Stem Cells Int. 2017;2017:1–12.CrossRef
55.
Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y, Tanaka S, et al. Mesenchymal stem cells induce epithelial to mesenchymal transition in colon cancer cells through direct cell-to-cell contact. Neoplasia. 2017;19(5):429–38.PubMedPubMedCentralCrossRef
56.
Takizawa N, Okubo N, Kamo M, Chosa N, Mikami T, Suzuki K, et al. Bone marrow-derived mesenchymal stem cells propagate immunosuppressive/anti-inflammatory macrophages in cell-to-cell contact-independent and -dependent manners under hypoxic culture. Exp Cell Res. 2017;358(2):411–20.PubMedCrossRef
57.
Niu X, Gupta K, Yang JT, Shamblott MJ, Levchenko A. Physical transfer of membrane and cytoplasmic components as a general mechanism of cell-cell communication. J Cell Sci. 2009;122(5):600–10.PubMedCrossRef
58.
Strassburg S, Hodson NW, Hill PI, Richardson SM, Hoyland JA. Bi-directional exchange of membrane components occurs during co-culture of mesenchymal stem cells and nucleus pulposus cells. PLoS ONE. 2012;7(3):e33739.PubMedPubMedCentralCrossRef
59.
Pasquier J, Guerrouahen BS, Al Thawadi H, Ghiabi P, Maleki M, Abu-Kaoud N, et al. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med. 2013;11(1):94.PubMedPubMedCentralCrossRef
60.
Kshitiz DA, Afzal J, Suhail Y, Ahn EH, Goyal R, Hubbi ME, et al. Control of the interface between heterotypic cell populations reveals the mechanism of intercellular transfer of signaling proteins. Integr Biol. 2015;7(3):364–72.CrossRef
61.
Sinclair KA, Yerkovich ST, Hopkins PM-A, Chambers DC. Characterization of intercellular communication and mitochondrial donation by mesenchymal stromal cells derived from the human lung. Stem Cell Res Ther. 2016;7(1):91.PubMedPubMedCentralCrossRef
62.
Ferrand J, Noël D, Lehours P, Prochazkova-Carlotti M, Chambonnier L, Ménard A, et al. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS ONE. 2011;6(5):e19569.PubMedPubMedCentralCrossRef
63.
Bartosh TJ, Ullah M, Zeitouni S, Beaver J, Prockop DJ. Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proc Natl Acad Sci. 2016;113(42):E6447–56.PubMedCrossRefPubMedCentral
64.
Plotnikov EY, Khryapenkova TG, Galkina SI, Sukhikh GT, Zorov DB. Cytoplasm and organelle transfer between mesenchymal multipotent stromal cells and renal tubular cells in co-culture. Exp Cell Res. 2010;316(15):2447–55.PubMedCrossRef
65.
66.
67.
Rutenberg MS, Hamazaki T, Singh AM, Terada N. Stem cell plasticity, beyond alchemy. Int J Hematol. 2004;79(1):15–21.PubMedCrossRef
68.
Podbilewicz B. Cell fusion. Pasadena: WormBook; 2006.
69.
Sumer H, Kim K, Liu J, Ng K, Daley GQ, Verma PJ. Functional evaluation of ES-somatic cell hybrids in vitro and in vivo. Cell Reprogram. 2014;16(3):167–74.PubMedPubMedCentralCrossRef
70.
Zhang Y, Yang Y, Zhu Z, Ou G. WASP-Arp2/3-dependent actin polymerization influences fusogen localization during cell–cell fusion in Caenorhabditis elegans embryos. Biol Open. 2017;6(9):1324–8.PubMedPubMedCentralCrossRef
71.
72.
Metadata
Title
Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells
Authors
Evgeniya V. Dolgova
Daria D. Petrova
Anastasia S. Proskurina
Genrikh S. Ritter
Polina E. Kisaretova
Ekaterina A. Potter
Yaroslav R. Efremov
Sergey I. Bayborodin
Tatiana V. Karamysheva
Margarita V. Romanenko
Sergey V. Netesov
Oleg S. Taranov
Aleksandr A. Ostanin
Elena R. Chernykh
Sergey S. Bogachev
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0842-x

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Uev1A promotes breast cancer cell survival and chemoresistance through the AKT-FOXO1-BIM pathway

Primary research

Protective potential of miR-146a-5p and its underlying molecular mechanism in diverse cancers: a comprehensive meta-analysis and bioinformatics analysis

Primary research

RETRACTED ARTICLE: Circular RNA ABCB10 promotes hepatocellular carcinoma progression by increasing HMG20A expression by sponging miR-670-3p

Primary research

Contribution of voltage-gated sodium channel β-subunits to cervical cancer cells metastatic behavior

Primary research

Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma

Primary research

miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits